Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT00666848 Completed - Hypertension Clinical Trials

Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome

Start date: March 2008
Phase: Phase 4
Study type: Interventional

This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure in individuals with the metabolic syndrome. We will also measure the effect of sitagliptin on blood pressure in people already taking a blood pressure medication called an ACE inhibitor.

NCT ID: NCT00666029 Completed - Metabolic Syndrome Clinical Trials

Implications for Treatment of the Metabolic Syndrome

Start date: February 2006
Phase: Phase 2
Study type: Interventional

To characterize features of metabolic syndrome in volunteers. To undertake a randomised trial to determine whether treatment with a statin improves muscle microvascular blood flow.

NCT ID: NCT00665834 Completed - Dyslipidemia Clinical Trials

Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

Start date: April 2006
Phase: Phase 4
Study type: Interventional

This is a 3-month, randomized, parallel-group study with 2 periods, comparing the efficacy and the safety of rosuvastatin 20 mg versus atorvastatin 80 mg in patients with an acute coronary syndrome (ACS).

NCT ID: NCT00665171 Not yet recruiting - Clinical trials for Polycystic Ovary Syndrome

Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome

Start date: June 2008
Phase: N/A
Study type: Observational

Background: Infertility affects up to 15% of married couples. About half are attributable to female factors, among which anovulation is the leading cause. Some 5% of all women of reproductive age are anovulatory due to the polycystic ovarian syndrome (PCOS). PCOS causes also major health and cosmetic problems and significantly affects quality of life. PCOS is associated with cardiovascular morbidity and Type 2 diabetes mellitus, but it is unclear whether these are caused by the ovarian dysfunction or result from a common denominator. Working hypothesis and aims: Whole genome analysis of multigenerational families in which at least one woman is affected by PCOS may significantly reduce the numbers needed to verify the specific genes, involved in the causation of PCOS. Methods: Registration of multigenerational families and production of personal files with full workup for the presence of PCOS or its absence (in the women participants). Drawing of blood, extraction and preservation of DNA. Analysis of all informative SNPs in the genomes of the participants on a specific microarray chip. Statistical analysis of the results. Expected results: Verification of the loci and putative genes, associated with the appearance of PCOS. Importance: Elucidation of the specific genes underlying the pathology of PCOS. Probable implications to Medicine: Paving the way for targeted treatment of the problems, associated with PCOS, based on the clear knowledge of its underlying cause(s).

NCT ID: NCT00665041 Completed - Clinical trials for Ovarian Hyperstimulation Syndrome

Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome

Start date: May 2008
Phase: Phase 2
Study type: Interventional

Assess the tolerability of quinagolide 200 μg/day in a dose-titration regimen in oocyte donors undergoing controlled ovarian hyperstimulation and at risk of developing OHSS Secondary Objectives Estimate the effects of a quinagolide dose-titration regimen compared to placebo in peritoneal fluid accumulation, incidence of ascites, OHSS symptoms and clinical laboratory parameters of haemoconcentration

NCT ID: NCT00664742 Completed - Metabolic Syndrome Clinical Trials

The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome

Start date: September 2006
Phase: Phase 4
Study type: Interventional

This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome

NCT ID: NCT00664300 Completed - Clinical trials for Gilles de la Tourette's Syndrome

Facial Expression Recognition of Emotion and Categorization of Emotional Words in Gilles de la Tourette's Syndrome

Start date: August 2007
Phase: N/A
Study type: Observational

Gilles de la Tourette's syndrome is a childhood onset inherited neuropsychiatric disorder characterised by the presence of both multiple motor tics and one or more vocal tics (noises), with psychiatric and/or behaviour disorders (such as obsessive compulsive behaviour…). This disease is associated with an dopamine system imbalance which could be responsible of a specific trouble in the recognition in some facial expression. This has been already shown in Gilles de la Tourette patients with obsessive compulsive behaviour. We hypothesise that patients with Gilles de la Tourette's syndrome present a dysfunction of voluntary and automatic treatment of emotional information. The main purpose of this study is to show if patients with Gilles de la Tourette's syndrome present a lack of specific facial expression recognition of emotion and determinate more precisely if this alteration involves the cortical way (high frequency way) or the under cortical way (low frequency way).

NCT ID: NCT00663897 Completed - Clinical trials for Functional Dyspepsia

Lansoprazole Versus Mosapride for Functional Dyspepsia

Start date: May 2008
Phase: Phase 4
Study type: Interventional

Functional dyspepsia is a common symptom complex with significant impact on quality of life. There is no standard treatment for functional dyspepsia but therapeutic efficacy of proton pump inhibitor (PPI) and prokinetic agent have been proved in subsets of patients. This study has two aims: - first is to compare the therapeutic efficacy of lansoprazole (a PPI) and mosapride (a prokinetic agent) for functional dyspepsia - second is to investigate whether different subgroups of functional dyspepsia (e.g., epigastric pain syndrome and postprandial distress syndrome) respond differently to PPI and prokinetic agent.

NCT ID: NCT00663104 Terminated - Coronary Disease Clinical Trials

Effect of Exercise and Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause

Start date: April 2008
Phase: Phase 3
Study type: Interventional

The aim of the study is to compare the effect of a progressive, periodized exercise training designed to impact bone, CHD-risk-factors and menopausal complaints versus the combined effect of exercise and "phytoestrogen" (cimicifuga racemosa; CR). After randomization, 84 females 1-3 year postmenopausal with no medication or illness affecting bone metabolism exercise over 12 months (EG; 42 with, 42 without CR), 42 women serve as wellness-control. Three group training sessions/week will be performed in the EG. Both groups will be individually supplemented with calcium and Vit-D (cholecalciferol).

NCT ID: NCT00662090 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood

EWOG MDS 2006
Start date: January 2006
Phase:
Study type: Observational

The aim of the study is to improve the accuracy of diagnosis for children and adolescents with MDS by a standardized review of morphology and standardized cytogenetic and molecular analysis. The primary objectives of the study are: - To evaluate the frequency of the different subtypes of MDS in childhood and adolescence by a standardized diagnostic approach - To evaluate the frequency of cytogenetic and molecular abnormalities: Specifically using array-CGH to evaluate the frequency of subtle chromosomal imbalances, i.e. gains and losses of defined chromosomal regions, and amplifications. Specifically using mFISH to identify unknown chromosomal aberrations, particularly subtle translocations involving new candidate genes, and to better define chromosomal breakpoints. The secondary objectives of the study are: - To assess survival for children and adolescents with MDS and JMML - To evaluate relapse rate, morbidity and mortality in children with MDS and JMML treated by HSCT